TB-500

Overview

TB-500 is the name attached to a peptide product sold and circulated as a research material and widely described as a "fragment of thymosin beta-4 (Tβ4)." Thymosin beta-4 is a small, naturally occurring 43-amino-acid protein that is among the most abundant actin-sequestering peptides in mammalian cells and has been studied for roles in cell migration, angiogenesis (blood-vessel formation), and wound healing.

The important distinction, explored in detail below, is that TB-500 and full-length thymosin beta-4 are not the same molecule. Analytical chemistry work that examined material sold as "TB-500" identified it as the N-terminal acetylated 17–23 fragment of Tβ4 (Ac-LKKTETQ), i.e. the short actin-binding motif of the protein rather than the whole protein (Esposito et al., 2012). Much of the encouraging biological literature people cite for "TB-500" is in fact research on full-length Tβ4, and almost all of it is animal or in-vitro work.

Chemistry and structure

The single most consequential fact about TB-500 is what it actually is at the molecular level, because the marketing name and the underlying science do not line up cleanly.

Full-length thymosin beta-4 (Tβ4) is a 43-amino-acid, N-terminally acetylated peptide with no cysteine residues (and therefore no disulfide bonds). Its human sequence is:

Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES

Within that sequence, residues 17–23 (LKKTETQ) form the principal actin-binding motif, which several studies identify as central to Tβ4's cell-binding and angiogenic activity (Philp et al., 2003).

TB-500, as analytically characterized in material seized or sampled from the doping market, corresponds to the acetylated 17–23 fragment alone, Ac-LKKTETQ, a 7-residue peptide, not the full 43-residue protein (Esposito et al., 2012).

Mechanism of action

Proposed mechanisms come almost entirely from in-vitro and animal experiments on thymosin beta-4, with the assumption (not directly established for the fragment in humans) that the actin-binding motif carries much of the relevant activity.

• Actin sequestration. Tβ4 binds monomeric G-actin, maintaining a pool of actin available for rapid polymerization. This is its best-characterized intracellular function and underlies its effects on the cytoskeleton and cell motility (Xing et al., 2021).
• Cell migration and angiogenesis via the actin-binding motif. The seven-residue motif (LKKTETQ) has been reported to drive endothelial-cell adhesion, sprouting, and angiogenesis, with the isolated motif and full Tβ4 showing near-identical activity in some assays (Philp et al., 2003). Tβ4 has also been linked to up-regulation of vascular endothelial growth factor (VEGF).
• Integrin-linked kinase (ILK) / Akt signaling. In a cardiac-injury model, Tβ4 was reported to form a complex with PINCH and ILK and to activate the survival kinase Akt, promoting cardiac-cell migration and survival (Bock-Marquette et al., 2004).
• Wound healing and tissue remodeling. Tβ4 is associated with accelerated re-epithelialization, reduced inflammation, and increased collagen deposition in dermal-wound models (Xing et al., 2021; Xu et al., 2013).

Research and evidence

The evidence base must be read with two filters in mind: (1) most studies use full-length Tβ4, not TB-500; and (2) the human data that exist are for Tβ4, not the fragment. The table labels evidence type explicitly.

In-vitro and animal evidence (mostly Tβ4)

The actin-binding motif's role in angiogenesis was shown in endothelial assays in which Tβ4 and the isolated LKKTETQ peptide displayed near-identical pro-angiogenic activity (Philp et al., 2003). Dermal-wound models report that Tβ4 accelerates re-epithelialization and wound contraction relative to controls, and an engineered dimeric Tβ4 accelerated closure further in rats (Xu et al., 2013). In a mouse cardiac-injury study, Tβ4 improved cardiac-cell survival and function via ILK/Akt signaling (Bock-Marquette et al., 2004). These findings are animal- and cell-based, and most used the full protein, not TB-500.

Human evidence — none for TB-500

There are no completed, published human clinical trials of TB-500 (the Ac-LKKTETQ fragment) for any tissue-repair or performance indication. This is a crucial and frequently obscured point.

Where human data exist, they concern full-length thymosin beta-4 developed as a pharmaceutical candidate (for example, programs in chronic dermal wounds and ophthalmic surface disease). A European randomized, placebo-controlled study evaluated topical Tβ4 in patients with venous stasis ulcers and reported it was generally well tolerated, with healing effects described as preliminary (Guarnera et al., 2007; see also the registered study NCT00832091). None of this human work studied the TB-500 fragment, and none has produced an approved product.

Status and regulation

TB-500 has not received marketing approval from any major regulator. It is not an approved drug and does not qualify as a dietary supplement; it circulates as an unregulated research chemical, typically labeled "for research use only, not for human consumption."

Full-length thymosin beta-4 has been studied as an investigational drug (under designations such as RGN-352 and RGN-259), but those programs are distinct from the TB-500 fragment and have not yielded an approved therapy as of this writing. Because TB-500 is sold outside any pharmaceutical quality system, its identity, purity, and dose accuracy are not guaranteed.

Safety and risks

Documented safety information for TB-500 specifically is essentially absent, because there are no human trials and little dedicated toxicology of the fragment. What follows is therefore largely extrapolation and theoretical concern, not established human safety data.

• No human safety data for the fragment. There are no controlled human trials, no pharmacovigilance data, and no established human pharmacokinetics for TB-500. "No reported problems" is not the same as "shown to be safe."
• Pro-angiogenic activity and cancer caution. Tβ4's pro-angiogenic and pro-migratory properties are a double-edged sword. Overexpression of Tβ4 has been reported to increase tumor metastasis and tumor angiogenesis in melanoma models (Cha et al., 2003), and Tβ4 has been linked to epithelial–mesenchymal transition in some cancers. A pro-angiogenic, pro-migratory agent could, in principle, support tumor growth or spread; this is a recognized theoretical reason for caution, not a demonstrated clinical outcome.
• Unknown long-term effects. Chronic effects, immunogenicity, and interactions are uncharacterized in humans for the fragment.
• Product-quality risk. As an unregulated research material, TB-500 may be mislabeled, contaminated, or of variable potency, a safety concern independent of the molecule's intrinsic properties.

Legal status

• United States. Not an approved drug and not a lawfully marketed dietary supplement (peptides of this type do not meet the dietary-ingredient definition). Commonly sold labeled "for research use only, not for human consumption."
• Sport. TB-500 is prohibited in sport at all times (in- and out-of-competition). The World Anti-Doping Agency (WADA) lists thymosin-β4 and its derivatives, explicitly naming TB-500, under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), among growth factors affecting muscle, tendon, or ligament. It has appeared on the Prohibited List since 2011 and remains prohibited on the current list. As a non-approved substance it may also fall under Section S0.
• Other jurisdictions. It is generally not approved as a medicine elsewhere; national rules on possession, import, and sale of unapproved peptides vary.

This entry is educational and does not constitute legal or medical advice.

How it compares

The table below sets TB-500 against its parent protein (full-length thymosin beta-4) and against BPC-157, the peptide it is most often discussed alongside in injury-recovery contexts. The central point: none of these has robust human efficacy data, and TB-500 specifically has no human trials at all.

Versus full-length Tβ4: TB-500 is not the same molecule. It is the short actin-binding fragment, lacking the regions of the protein that govern its broader signaling and pharmacokinetics. Almost all favorable biology, including the limited human work, describes the full protein, not the fragment.

Versus BPC-157: the two are chemically unrelated (different sequences, different proposed mechanisms) and are paired by convention in recovery discussions rather than by shared evidence. Both are preclinical: BPC-157 has no human efficacy trials either, and neither peptide is approved for any indication.

Common misconceptions

• "TB-500 is thymosin beta-4." The product analyzed as TB-500 is the short Ac-LKKTETQ fragment (residues 17–23), not the full 43-amino-acid protein. They differ in sequence, size, and pharmacokinetics.
• "TB-500 is clinically proven to heal injuries." There are no human trials of TB-500. The supportive evidence is animal and in-vitro, and most of it studied full-length Tβ4.
• "It's a natural substance, so it's safe." Tβ4 is naturally occurring, but TB-500 is a synthesized fragment, and natural origin does not establish safety, especially given the pro-angiogenic/cancer caution.
• "It's FDA-approved or a legal supplement." It is neither. It is an unapproved research chemical and is prohibited in sport.
• "TB-500 and BPC-157 are the same / interchangeable." They are distinct peptides with different sequences and mechanisms, frequently discussed together by convention rather than because of established combined evidence. See the entry on BPC-157 for a separate, similarly limited evidence profile.

Community claims & recent evidence

These points address claims circulating in the peptide community — including popular video "masterclasses" — checked against primary sources. As throughout this entry, note that almost all of this biology is full-length thymosin beta-4 (Tβ4) in animals, not the Ac-LKKTETQ fragment sold as TB-500, and none of it is human data for the fragment.

Verified additions

• Stroke recovery (animal). In a rat embolic-stroke model, Tβ4 given 24 h after the stroke and repeated improved functional neurological outcome, an effect the authors attribute to neurorestoration rather than acute neuroprotection [Animal] (Morris et al., Neuroscience 2010).
• Traumatic brain injury (animal). After experimental TBI in rats, Tβ4 promoted neurogenesis, oligodendrogenesis and angiogenesis and improved functional recovery [Animal] (Xiong et al., Annals of the New York Academy of Sciences 2012).
• Renal fibrosis (animal). In unilateral-ureteral-obstruction rat kidneys, Tβ4 attenuated interstitial fibrosis and tubular-cell apoptosis, associated with inhibition of TGF-β signalling [Animal] (Yuan et al., BMC Nephrology 2017).
• Cardiac fibrosis (animal). Beyond the migration/survival effects already described elsewhere in this entry, Tβ4 reduced cardiac fibrosis and improved left-ventricular function after myocardial infarction in mice, in part by dampening TGF-β1-driven myofibroblast activation [Animal] (Wang et al., Cardiovascular Therapeutics 2022).

Claims that don't hold up

• "TB-500 cannot cause cancer because it isn't genotoxic — it actually suppresses cancer." Genotoxicity is a strawman: promoting angiogenesis, cell migration and epithelial–mesenchymal transition can worsen an existing cancer without mutating DNA, and that is precisely what Tβ4 does in models. Forced Tβ4 overexpression increased metastasis and tumour angiogenesis in melanoma [Animal] (Cha et al., Journal of the National Cancer Institute 2003), and Tβ4 drives EMT and tumour progression through a TGFβ/MRTF axis [In vitro/Animal] (Morita & Hayashi, Molecular Cancer Research 2018). The literature points the opposite way from the claim.
• "A PLoS One study showed TB-500 inhibits glioblastoma migration and invasion." This is inverted. Silencing Tβ4 decreased glioblastoma stemness and invasiveness and prolonged survival of tumour-bearing mice, and Tβ4 expression rises with glioma grade — i.e. Tβ4 promotes, not blocks, glioma invasion [In vitro/Animal] (Wirsching et al., Brain 2014).
• Named-journal citations that don't resolve. Several confident references ("2012 Journal of Pharmacology and Experimental Therapeutics," a "2016 Circulation Research" pericyte study, an "endocrinology" glucose study, a "Journal of Neurotrauma" paper) do not resolve to studies of TB-500. The real neuro, cardiac and renal work is on full-length Tβ4 in rodents (e.g. Neuroscience, Annals of the New York Academy of Sciences, BMC Nephrology). A specific journal-and-percentage citation that cannot be located is not evidence.
• "It crosses the blood–brain barrier and helps stroke victims reclaim lost brain function." The human clinical benefit is unfounded: the evidence is rodent Tβ4 (Morris et al., 2010), and no human trial of TB-500 exists for stroke or any other indication [Animal → overstated to Human].
• "It reverses existing fibrosis and regenerates heart-muscle cells." Overstated. Animal Tβ4 reduces fibrosis and is cardioprotective, but frank cardiomyocyte regeneration and scar reversal are contested even in animals and unshown in humans [Animal/Hypothesis].
• Conflating TB-500 with thymosin beta-4. The masterclass uses "TB-500" and "thymosin beta-4" interchangeably. Every mechanism and organ claim it lists is full-length Tβ4, overwhelmingly in animals; none tested the Ac-LKKTETQ fragment actually sold as TB-500, and none was in humans.